Cost-Effectiveness of Losartan Versus Atenolol in Treating Hypertension—An Analysis of the LIFE Study from a Swiss Perspective
Authors: Szucs, Thomas1; Burnier, Michel2; Erne, Paul3
Source: Cardiovascular Drugs and Therapy, Volume 18, Number 5, September 2004 , pp. 391-397(7)
Publisher: Springer
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Abstract:
Aims: To determine the economic benefit of losartan versus atenolol in patients with essential hypertension from the perspective of the Swiss healthcare system. Methods and results: The cost-effectiveness of losartan versus atenolol in the treatment of hypertension was analyzed by applying the results of the LIFE study to the Swiss healthcare system using a decision analysis framework.The cost-effectiveness shows the losartan cohort to provide an additional life expectancy of 0.05 years per patient compared to the atenolol cohort, over a mean follow-up period of 4.8 years. Losartan therapy in hypertensive patients produced net cost savings of CHF 24 per patient and per 4.8 years compared to atenolol from the perspective of the Swiss health care system. This result was robust after varying costs of medication, stroke, myocardial infarction and life expectancy. Conclusion: The use of a losartan-based regimen in hypertensive patients with left ventricular hypertrophy in Switzerland is net cost-saving compared with a atenolol-based regimen.Keywords: cost-effectiveness; medical economics; hypertension; stroke losartan; atenolol; LIFE
Document Type: Research article
DOI: 10.1007/s10557-005-5064-x
Affiliations: 1: Institute of Social- and Preventive Medicine, 011011011011011011011011University Zurich, Zurich, Email: thomas.szucs@ifspm.unizh.ch 2: Department of Internal Medicine, 011011011011011011011011Centre Hospitalier Universitaire Vaudois, Lausanne, 3: Cardiology Department, 011011011011011011011011Kantonsspital Luzern, Luzern,
- Free Content
- New Content
- Subscribed Content
- Free Trial Content
Click here for Page Help